gms | German Medical Science

63rd Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Japanese Neurosurgical Society (JNS)

German Society of Neurosurgery (DGNC)

13 - 16 June 2012, Leipzig

The role of PTHrP in meningioma bone invasion

Meeting Abstract

  • M.A. Proescholdt - Klinik für Neurochirurgie, Universitätsklinikum Regensburg
  • E.M. Störr - Klinik für Neurochirurgie, Universitätsklinikum Regensburg
  • A. Lohmeier - Klinik für Neurochirurgie, Universitätsklinikum Regensburg
  • A. Brawanski - Klinik für Neurochirurgie, Universitätsklinikum Regensburg

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocDO.03.04

DOI: 10.3205/12dgnc040, URN: urn:nbn:de:0183-12dgnc0409

Published: June 4, 2012

© 2012 Proescholdt et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Invasion of the adjacent bone has been shown to be a risk factor for recurrence and poor prognosis in meningiomas. However, the molecular mechanism for this process is unknown. Parathyroid hormone related protein (PTHrP) causes osteoclast activation and mediates bone metastasis in different cancer types. We hypothesized that PTHrP is also a mediator of meningioma specific bone invasion. We therefore analyzed the PTHrP expression in bone invasive and non-invasive meningiomas. In addition, we stimulated meningioma cell cultures with bone derived growth factors such as transforming growth factor (TGF) beta 1&2, which are known to induce PTHrP expression. Using RNA interference, PTHrP expression was knocked down. Subsequently, we observed the bone invasiveness utilizing a tumor - bone co-culture assay.

Methods: 66 meningioma samples (30 with, 36 without bone invasion) were analyzed for PTHrP expression by immunohistochemistry, Western Blot and RTPCR. Meningioma cell culture was established from 21 tumors resected from 7 male (33.4%) and 14 female (66.6%) patients, with a mean age of 62.7 years (range: 43–82 years). The cell cultures were treated with TGF beta 1&2 at 10 ng/ml. Gene knockdown was performed by transfection with a PTHrP siRNA construct utilizing lipofectamine as transfection reagent. As control served a non specific sequence siRNA. Bone invasion was analyzed by co-cultivation of meningioma cells with neonatal mouse calvariae. The invading cells were visualized with immunofluorescent staining for human HLA.

Results: The bone invasive meningioma samples showed significant higher PTHrP expression both at the mRNA and the protein level. Treatment with TGF beta 1&2 strongly enhanced meningioma bone invasion in vitro which was again significantly reduced by PTHrP knockdown.

Conclusions: Our data show that that PTHrP is overexpressed in bone invasive meningiomas. Induction and gene knockdown experiments indicate that PTHrP plays an important functional role in menigioma bone invasion.